Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette's syndrome: A pilot study
Chappell P, Leckman J, Scahill L, Hardin M, Anderson G, Cohen D. Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette's syndrome: A pilot study. Psychiatry Research 1993, 47: 267-280. PMID: 8396784, DOI: 10.1016/0165-1781(93)90084-t.Peer-Reviewed Original ResearchConceptsNormal control subjectsTourette syndromeTic frequencyControl subjectsTS patientsMicrograms/Clinician ratingsKappa agonist spiradolineInvolvement of opioidRole of opioidsGrowth hormone secretionDual modulatory effectsDose-response studyMotor tic frequencyMore growth hormoneTic symptomsHormone secretionNeuroendocrine effectsKappa receptorsPhonic ticsSpiradoline mesylateIntermediate doseLow doseModulatory effectsSpiradoline